Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1964 1
1965 4
1966 1
1967 2
1969 2
1970 3
1971 4
1972 5
1973 9
1974 4
1975 5
1976 4
1977 7
1978 14
1979 15
1980 3
1981 8
1982 8
1983 11
1984 19
1985 19
1986 11
1987 14
1988 14
1989 6
1990 13
1991 6
1992 7
1993 14
1994 13
1995 19
1996 11
1997 7
1998 5
1999 22
2000 7
2001 9
2002 8
2003 13
2004 14
2005 8
2006 11
2007 16
2008 9
2009 12
2010 17
2011 14
2012 15
2013 13
2014 10
2015 16
2016 15
2017 31
2018 22
2019 18
2020 16
2021 25
2022 28
2023 18
2024 19
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

659 results

Results by year

Filters applied: . Clear all
Page 1
Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy.
Fukushima H, Furusawa A, Kato T, Wakiyama H, Takao S, Okuyama S, Choyke PL, Kobayashi H. Fukushima H, et al. Among authors: okuyama s. Mol Cancer Ther. 2023 Oct 2;22(10):1215-1227. doi: 10.1158/1535-7163.MCT-23-0210. Mol Cancer Ther. 2023. PMID: 37461129 Free PMC article.
Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases.
Inagaki FF, Wakiyama H, Furusawa A, Okada R, Kato T, Fujimura D, Okuyama S, Fukushima H, Takao S, Choyke PL, Kobayashi H. Inagaki FF, et al. Among authors: okuyama s. Biomed Pharmacother. 2023 Apr;160:114390. doi: 10.1016/j.biopha.2023.114390. Epub 2023 Feb 13. Biomed Pharmacother. 2023. PMID: 36791566 Free PMC article.
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.
Panse J, Daguindau N, Okuyama S, Peffault de Latour R, Schafhausen P, Straetmans N, Al-Adhami M, Persson E, Wong RSM. Panse J, et al. Among authors: okuyama s. PLoS One. 2024 Jul 29;19(7):e0306407. doi: 10.1371/journal.pone.0306407. eCollection 2024. PLoS One. 2024. PMID: 39079163 Free PMC article. Clinical Trial.
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Ueno M, Takeda H, Takai A, Morimura H, Nishijima N, Iwamoto S, Okuyama S, Umeda M, Seta T, Ikeda A, Goto T, Miyamoto S, Kayahara T, Uenoyama Y, Matsumura K, Nakano S, Mishima M, Inuzuka T, Eso Y, Takahashi K, Marusawa H, Osaki Y, Hatano E, Seno H. Ueno M, et al. Among authors: okuyama s. J Gastroenterol. 2024 Dec;59(12):1107-1118. doi: 10.1007/s00535-024-02150-7. Epub 2024 Sep 18. J Gastroenterol. 2024. PMID: 39289234 Free PMC article.
[Preface].
Miyamoto L, Okuyama S. Miyamoto L, et al. Among authors: okuyama s. Nihon Yakurigaku Zasshi. 2020;155(4):201. doi: 10.1254/fpj20026. Nihon Yakurigaku Zasshi. 2020. PMID: 32612028 Japanese. No abstract available.
[Idiosyncratic drug toxicity].
Yamada H, Yamaguchi J, Iida I, Okuyama S. Yamada H, et al. Among authors: okuyama s. Nihon Yakurigaku Zasshi. 2006 Jun;127(6):473-80. doi: 10.1254/fpj.127.473. Nihon Yakurigaku Zasshi. 2006. PMID: 16880698 Review. Japanese. No abstract available.
659 results